Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutrepulse via OmniPod in healthy females
NCT07152730Phase 1Withdrawn
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gonadorelin in hypothalamic amenorrhea (HA) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at 5 days, Area Under the Concentration-Time Profile to the Last Quantified Concentration at 5 days and 1 more. Planned start Sep 2025; status: withdrawn.
02
Drugs
gonadorelin
03
Conditions
hypothalamic amenorrhea (HA)
Beyond the preview
Go deeper on NCT07152730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152730.